Silo Pharma (NASDAQ: SILO) filed a provisional patent application with the United States Patent and Trademark Office for ibogaine-based therapeutics to treat traumatic brain injury and related neuropsychiatric conditions, according to a company statement.

The patent application, titled "Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine," covers the use of ibogaine and related compounds for treating TBI, post-traumatic stress disorder and associated conditions.

The filing aligns with an Executive Order by President Trump announced April 18, 2026, under which the FDA granted Breakthrough Therapy designation to specific psychedelic drugs through a program designed to expedite development and review of drugs for serious or life-threatening conditions.

"While many drugs are used off label to manage TBI symptoms like cognitive dysfunction or depression, no pharmaceutical agent has ever received FDA approval for the direct treatment of TBI," said Eric Weisblum, CEO of Silo Pharma.

No FDA-approved treatments currently address structural or regenerative aspects of traumatic brain injury. Current treatment options are limited to symptomatic support.

The global traumatic brain injury therapeutics market is estimated to reach $6.0 billion by 2032, growing at a compound annual growth rate of 6.0% between 2025 and 2032, according to Persistence Market Research.

Silo Pharma plans to evaluate ibogaine and related compounds as part of its strategy to develop psychedelics-assisted central nervous system therapeutics. The company intends to explore treatment approaches designed to promote neuroplasticity and improve functional outcomes.

The developmental-stage biopharmaceutical company focuses on therapeutics for stress-induced psychiatric disorders, chronic pain and central nervous system diseases.